Genesis Therapeutics

Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery.

We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines.

Genesis raised its $52M Series A from top tech + biotech investors, Andreessen Horowitz, Rock Springs, and T. Rowe Price.

Story: https://techcrunch.com/2020/12/02/genesis-therapeutics-raises-52m-a-round-for-its-ai-focused-drug-discovery-mission/

We deploy our technology to accelerate a pipeline of several internal drug programs.

Furthermore, Genesis has announced two significant, multi-target collaborations with Genentech and with Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size.

Now we are scaling the team and technology to support many more programs in parallel as well as increasingly difficult protein targets.
We currently have a team (genesistherapeutics.ai/company.html#team) of about 35 people, split 50/50 between our ML / software team and our biochem team of veteran drug hunters in our own wetlab space. Our ML + software engineers are top-notch -- many graduates from MIT, UC Berkeley, Stanford. Previously worked at OpenAI, Google, Facebook, MemSQL, Jane Street, Dropbox, etc.

We're recruiting pure ML research scientists + software engineers (no bio or chem experience expected) to further our core AI platform as well as scale our drug pipeline.

Likewise, we have several openings in chemistry and biology to join our team of biotech + pharma veterans who are deploying the Genesis ML platform to discover novel drug candidates.

Please apply on our website, or feel free to reach out via email directly: [email protected]